SE462829B - Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas - Google Patents

Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas

Info

Publication number
SE462829B
SE462829B SE8900067A SE8900067A SE462829B SE 462829 B SE462829 B SE 462829B SE 8900067 A SE8900067 A SE 8900067A SE 8900067 A SE8900067 A SE 8900067A SE 462829 B SE462829 B SE 462829B
Authority
SE
Sweden
Prior art keywords
modified
domain
normal human
active composition
component
Prior art date
Application number
SE8900067A
Other languages
English (en)
Swedish (sv)
Other versions
SE8900067D0 (sv
Inventor
G Pohl
Original Assignee
Kabigen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabigen Ab filed Critical Kabigen Ab
Priority to SE8900067A priority Critical patent/SE462829B/sv
Publication of SE8900067D0 publication Critical patent/SE8900067D0/xx
Priority to US07/459,210 priority patent/US5202121A/en
Priority to CA002007075A priority patent/CA2007075C/fr
Priority to AU47768/90A priority patent/AU624466B2/en
Priority to AT90850008T priority patent/ATE80308T1/de
Priority to EP90850008A priority patent/EP0381640B1/fr
Priority to ES90850008T priority patent/ES2044534T3/es
Priority to DE9090850008T priority patent/DE69000290T2/de
Priority to DK90850008.5T priority patent/DK0381640T3/da
Priority to JP2001149A priority patent/JP2958650B2/ja
Publication of SE462829B publication Critical patent/SE462829B/sv
Priority to GR920402378T priority patent/GR3006053T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8900067A 1989-01-10 1989-01-10 Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas SE462829B (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE8900067A SE462829B (sv) 1989-01-10 1989-01-10 Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas
US07/459,210 US5202121A (en) 1989-01-10 1989-12-29 Thrombolytic compositions
CA002007075A CA2007075C (fr) 1989-01-10 1990-01-03 Nouveaux composes thrombolytiques
DK90850008.5T DK0381640T3 (da) 1989-01-10 1990-01-08 Thrombolytiske præparater
AT90850008T ATE80308T1 (de) 1989-01-10 1990-01-08 Thrombotische zusammensetzungen.
AU47768/90A AU624466B2 (en) 1989-01-10 1990-01-08 New thrombolytic compositions
EP90850008A EP0381640B1 (fr) 1989-01-10 1990-01-08 Compositions trombolitiques
ES90850008T ES2044534T3 (es) 1989-01-10 1990-01-08 Un metodo para la preparacion de una composicion tromboliticamente activa.
DE9090850008T DE69000290T2 (de) 1989-01-10 1990-01-08 Thrombotische zusammensetzungen.
JP2001149A JP2958650B2 (ja) 1989-01-10 1990-01-09 新規な血栓溶解組成物
GR920402378T GR3006053T3 (fr) 1989-01-10 1992-10-22

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8900067A SE462829B (sv) 1989-01-10 1989-01-10 Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas

Publications (2)

Publication Number Publication Date
SE8900067D0 SE8900067D0 (sv) 1989-01-10
SE462829B true SE462829B (sv) 1990-09-10

Family

ID=20374707

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8900067A SE462829B (sv) 1989-01-10 1989-01-10 Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas

Country Status (11)

Country Link
US (1) US5202121A (fr)
EP (1) EP0381640B1 (fr)
JP (1) JP2958650B2 (fr)
AT (1) ATE80308T1 (fr)
AU (1) AU624466B2 (fr)
CA (1) CA2007075C (fr)
DE (1) DE69000290T2 (fr)
DK (1) DK0381640T3 (fr)
ES (1) ES2044534T3 (fr)
GR (1) GR3006053T3 (fr)
SE (1) SE462829B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682733B1 (en) * 1987-06-18 2004-01-27 Roche Diagnostics, Gmbh Fibrinolytic enzymes
GB8919803D0 (en) * 1989-09-01 1989-10-18 Ciba Geigy Pharmaceutical compositions
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8503097A (nl) * 1985-11-11 1987-06-01 Leuven Res & Dev Vzw Geneesmiddel met thrombolytische werking.
EP0293394B2 (fr) * 1986-01-31 2003-10-29 Genetics Institute, LLC Nouvelles proteines thrombolytiques
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
NL8701021A (nl) * 1987-04-29 1988-11-16 Stichting Centraal Lab Humane t-pa(u-pa) substitutie-mutant eiwitten, daarvoor coderend recombinant dna, getransfecteerde gastheercellen, bereiding van de mutant eiwitten, en farmaceutische preparaten.
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US4963357A (en) * 1987-10-09 1990-10-16 Monsanto Company Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor
DE3741149A1 (de) * 1987-12-04 1989-06-15 Thomae Gmbh Dr K Zubereitungsformen zur verhinderung von adhaesionen von organen und organteilen

Also Published As

Publication number Publication date
JPH02225420A (ja) 1990-09-07
ES2044534T3 (es) 1994-01-01
SE8900067D0 (sv) 1989-01-10
US5202121A (en) 1993-04-13
DE69000290T2 (de) 1993-04-22
GR3006053T3 (fr) 1993-06-21
ATE80308T1 (de) 1992-09-15
EP0381640B1 (fr) 1992-09-09
DK0381640T3 (da) 1992-12-21
CA2007075C (fr) 2002-03-19
AU624466B2 (en) 1992-06-11
JP2958650B2 (ja) 1999-10-06
AU4776890A (en) 1990-08-30
EP0381640A1 (fr) 1990-08-08
CA2007075A1 (fr) 1990-07-10
DE69000290D1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
Levine et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism
Vaughan et al. PGE1 accelerates thrombolysis by tissue plasminogen activator
Aoki Genetic abnormalities of the fibrinolytic system
Collen et al. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction
Been et al. Clinical effects and kinetic properties of intravenous APSAC—anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction
Back et al. Study on the effect of streptokinase-activated plasmin (fibrinolysin) on clots in various stages of organization
Pollak et al. Ancrod causes rapid thrombolysis in patients with acute stroke
Stassen et al. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator
Suzuki et al. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi
JP2820699B2 (ja) 血栓溶解剤
Cambier et al. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis
SE462829B (sv) Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas
US6534035B1 (en) Methods of inhibiting clot formation
Collen et al. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model
Ziskind et al. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Bergstein et al. Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction
WO1991001142A1 (fr) Combinaisons et procedes de traitement ou de prevention de maladies thrombotiques
EP0223192B1 (fr) Composition pharmaceutique à effet thrombolytique
Butler et al. Rapid localization of indium-111-labeled inhibited recombinant tissue plasminogen activator in a rabbit thrombosis model
WO2005074979A1 (fr) Utilisation de la prourokinase pour le traitement du syndrome pulmonaire thrombo-embolique ou de l'occlusion de l'artere centrale de la retine
PT85848B (en) Process for the preparation of pharmaceutical compounds with thrombolitic activity containing an urokinase and pro-urokinase synergic mixture
Cossum Pharmacologic basis for the safety assessment of recombinant human proteins
Maksimenko et al. Effective enzyme thrombolytic composition on the basis of wild-type and chemically modified plasminogen activators
WO2018232305A1 (fr) Procédés et compositions pour la thrombolyse
Kanke et al. Plasminogen Activator

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8900067-3

Format of ref document f/p: F

NUG Patent has lapsed